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Role of common cytokine receptor gchain (gc)– and Jak3-dependent signaling
in the proliferation and survival of murine mast cells
Kotaro Suzuki, Hiroshi Nakajima, Norihiko Watanabe, Shin-ichiro Kagami, Akira Suto, Yasushi Saito, Takashi Saito, and Itsuo Iwamoto
The regulatory roles of the common cyto-
kine receptor g chain (gc)– and Jak3-
dependent signaling in the proliferation
and survival of mast cells were deter-
mined using gc-deﬁcient (gc
2) and Jak3-
deﬁcient (Jak32) mice. Although the mast
cells in gc
2 and Jak32 mice were morpho-
logically indistinguishable from those in
wild-type mice, the number of peritoneal
mast cells was decreased in gc
2 and
Jak32 mice as compared with that in
wild-type mice. Among gc-related cyto-
kines, interleukin (IL)-4 and IL-9, but not
IL-2, IL-7, or IL-15, enhanced the prolifera-
tion and survival of bone marrow–derived
mast cells (BMMCs) from wild-type mice.
However, the effects of IL-4 and IL-9 were
absent in BMMCs from gc
2 and Jak32
mice. In addition, IL-4Ra, gc, and Jak3,
but not IL-2Rb or IL-7Ra, were expressed
in BMMCs. In contrast, IL-13 did not sig-
niﬁcantlyinducetheproliferationandsur-
vival of BMMCs even from wild-type mice,
and IL-13Ra1 was not expressed in BM-
MCs. Furthermore, IL-4 phosphorylated
the 65-kd isoform of Stat6 in BMMCs from
wild-type mice but not from gc
2 and Jak32
mice. These results indicate that gc- and
Jak3-dependent signaling is essential for
IL-4– and IL-9–induced proliferation and
survival of murine mast cells, that the
effects of IL-4 are mediated by type I IL-4R
and that type II IL-4R is absent on mast
cells, and that IL-4 phosphorylates the
65-kd isoform of Stat6 in mast cells in a
gc- and Jak3-dependent manner. (Blood.
2000;96:2172-2180)
© 2000 by TheAmerican Society of Hematology
Introduction
Mast cells are recognized as the major effector cells of the type I
hypersensitivityreactionsbyvirtueoftheirpossessinghigh-afﬁnity
receptors for immunoglobulin (Ig) E and are known to play a
pivotal role in allergic diseases, such as atopic rhinitis, asthma, and
atopic dermatitis.1,2 Mature mast cells are distributed throughout all
vascularized tissues, and the development and proliferation of mast
cells require proper signaling from several cytokines, among which
the c-kit/stem cell factor (SCF) system and interleukin (IL)-3 are
the best studied.1-4
The common cytokine receptor g chain (gc) is a shared
component of the receptors for IL-2, IL-4, IL-7, IL-9, and IL-15.5,6
Mutations in gc result in X-linked severe combined immunodeﬁ-
ciency (XSCID) in humans.7 Like humans with XSCID, mice in
which the gc gene has been disrupted by homologous recombina-
tion exhibit a hypoplastic thymus and are compromised in their
ability to respond to antigenic stimuli.8-10 Janus kinase 3 (Jak3) is a
tyrosine kinase that is known to transduce gc-dependent signals.11
Mutation of the Jak3 gene results in a form of severe combined
immunodeﬁciency (SCID) that is clinically and immunologically
indistinguishable from XSCID, except for the autosomal recessive
inheritance pattern in Jak3-deﬁcient SCID,12,13 which suggests the
essential role of Jak3 in gc-dependent signaling for lymphocyte
development. IL-7 appears to be the most important cytokine for
T-cell and B-cell development,14-16 whereas IL-15 seems to be
important for natural killer (NK) cell and NK T-cell develop-
ment.17-19 Among gc-related cytokines, IL-4,20-23 IL-9,24,25 and
IL-1526 have been reported to support the proliferation and survival
of mast cells.
IL-4 exerts a number of biologic activities in the hematopoietic
and immune system.27 IL-4 transduces the signals through 2 types
of IL-4 receptors (IL-4Rs): Type I IL-4R is a heterodimer of
IL-4Ra and gc, and type II IL-4R is a heterodimer of IL-4Ra and
IL-13Ra1.28,29 Type I IL-4R is preferentially expressed in hemato-
poietic cells, whereas type II IL-4R is preferentially expressed in
nonhematopoietic cells.28,29 However, in some hematopoietic cells,
including human B cells30,31 and murine macrophages,32 both types
of IL-4R are expressed, and IL-4 can transduce the signals in the
absence of gc through type II IL-4R. Recently, it has been shown
that IL-13, a cytokine that shares many biologic activities with
IL-4,33 also uses type II IL-4R for signal transduction.29 Although
previous studies have shown that IL-4 is a potent stimulator of mast
cell proliferation and survival,20-23 it remains unknown which type
of IL-4R is functional on mast cells. Furthermore, the role of IL-13
in mast cell growth also remains unclear.
IL-15 is a cytokine that shares many functional properties with
IL-2.34 Analysis of IL-15Ra-deﬁcient mice revealed that IL-15
played important roles in NK cell development and generation of
memory CD81 T cells.19 Recently, it was demonstrated that IL-15
induced mast cell proliferation through an undeﬁned receptor,
IL-15R X.26 Interestingly, Tagaya et al found that IL-15 activated
Jak2 in mast cells through IL-15R X,26 whereas IL-15 activated
Jak1 and Jak3 in T cells and NK cells through a heterodimer of
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signaling in mast cell proliferation is still largely unknown.
Although analyses of mice lacking gc and Jak3 have revealed
the importance of gc and Jak3 in T-cell and NK cell development in
vivo,8-11,35,36 the roles of gc and Jak3 in mast cell development
remain unclear. We present data that demonstrate an important
regulatory role of gc- and Jak3-dependent signals in the prolifera-
tion and survival of murine mast cells.
Materials and methods
Mice and genetic analysis
gc-Deﬁcient (gc
2) mice9 and Jak3-deﬁcient (Jak32) mice35 were back-
crossed to BALB/c mice (Jackson Laboratory, Bar Harbor, ME) for at least
6 generations. The mice were genotyped by polymerase chain reaction
(PCR) as described previously,36 and littermate wild-type (WT) mice were
used as controls. Mice were housed in microisolator cages under pathogen-
freeconditions.AllexperimentsfollowedtheguidelinesofChibaUniversity.
Culture of bone marrow–derived mast cells (BMMCs)
Primary culture of IL-3–dependent BMMCs was prepared from 8- to
12-week-old WT, gc
2, or Jak32 mice and maintained as described
previously.37 Brieﬂy, the mice were killed and bone marrow was ﬂushed
aseptically from femurs and tibias into RPMI 1640 medium containing 10%
heat-inactivated fetal calf serum (FCS), 50 mmol/L b-mercaptoethanol, 2
mmol/L L-glutamine, 1 mmol/L sodium pyruvate, 0.1 mmol/L nonessential
amino acids, antibiotics, and 10% (vol/vol) of murine IL-3 transfectant X63
cell conditioned medium38 (X63–IL-3; kindly provided by Dr H. Kara-
suyama, Tokyo Metropolitan Institute of Medical Science) as a source of
IL-3.The nonadherent bone marrow cells were then maintained at 37°C at a
density of 2 to 5 3 105 cells/mL in the same medium, with biweekly
replacement of old media with fresh ones. BMMCs obtained after 4 weeks
of culture were more than 98% mast cells, as demonstrated by morphologic
analysis, and BMMCs were used for the following experiment at 4 to 6
weeks of culture. In preliminary experiments, the maximum proliferation of
BMMCs was observed at 2% to 20% of X63–IL-3 conditioned medium.
Peritoneal lavage cells
Peritoneal lavage was performed by injecting 10 mLof ice-cold phosphate-
buffered saline (PBS) into the peritoneal cavity of the mouse.After the cells
were centrifuged (400g), resuspended in 1 mL of PBS, and counted using a
hemocytometer, differential cell counts were performed on cytospin cell
preparations stained with Wright-Giemsa solution. Peritoneal mast cells
were identiﬁed morphologically according to the criteria described previ-
ously.2,39 A fraction of the cells was subjected to ﬂow cytometric analysis
as follows.
Flow cytometric analysis
Cells from the peritoneal cavity and BMMCs were stained and analyzed on
a FACScaliber (Becton Dickinson, San Jose, CA) with CELLQuest
software. The following antibodies were purchased: anti-CD117 (c-kit)
ﬂuorescein isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin
(APC) (2B8; PharMingen, San Diego, CA), anti-CD122 (IL-2Rb)P E
(TM-b1; PharMingen), anti-gc PE (4G2; PharMingen), anti-CDw124
(IL-4Ra) (1688-01; Genzyme Corp, Cambridge, MA), anti-CD127 (IL-
7Ra) biotin (B12-1; PharMingen), anti-CD16/32 (FcgII/III) PE (2.4G2;
PharMingen), anti–Gr-1 APC (RB6-8C5; PharMingen), anti-CD4 APC
(RM4-5; PharMingen), anti-CD8APC (53-6.7; PharMingen), anti-CD45R/
B220 APC (RA3-6B2; PharMingen), and anti-rat IgG2a FITC (RG7/1.30;
PharMingen). Before staining, Fc receptors were blocked with anti-
CD16/32 antibody (2.4G2; PharMingen) excepting the detection of anti-
CD16/32 PE staining. Negative controls consisted of isotype-matched,
directly conjugated, nonspeciﬁc antibodies (PharMingen).
IgE receptors on mast cells
To quantify the levels of IgE receptors expressed on the cell surface, we ﬁrst
incubated the cells with mouse antitrinitrophenol IgE (IgE3; PharMingen)
at 4°C for 60 minutes to saturate the IgE receptors, and then labeled them
with anti-IgE FITC (R35-72; PharMingen). In some experiments, IgE
receptors on BMMCs were visualized directly by FITC-conjugated mouse
IgE (IgE3; PharMingen).
Cell survival assay
BMMCs were washed 3 times with PBS and cultured at 1 3 106 cells/mLin
triplicate at 37°C for 1 to 5 days in RPMI 1640 medium without IL-3 in the
presence of the indicated cytokines: murine IL-4 (20 ng/mL; Genzyme
Corp), murine IL-9 (20 ng/mL; PeproTech Inc, Rocky Hill, NJ), murine
IL-13 (20 ng/mL; R&D Systems, Minneapolis, MN), or human IL-15 (20
ng/mL and 129 ng/mL; DIACLONE Research, Besanc ¸on Cedex, France).
Cells were harvested and viability was determined by ﬂuorescence-
activated cell sorting (FACS) with 5 mg/mL of propidium iodide (PI)
(Boehringer Mannheim, Indianapolis, IN).40 To examine the survival of
peritoneal mast cells, we cultured freshly isolated cells from the peritoneal
cavity for 24 hours in RPMI 1640 medium without IL-3 in the presence of
murine IL-4 (20 ng/mL) or murine IL-9 (20 ng/mL). The viability of c-kit1
cells was determined by FACS with the use of anti–c-kit FITC and 5 mg/mL
of PI.
Proliferation assay
BMMCs (2 3 105/well) were cultured in triplicate at 37°C for 36 hours in
96-well plates in RPMI 1640 medium containing 10% (vol/vol) of
X63–IL-3 conditioned medium with the indicated cytokines: human IL-2
(20 ng/mL; R&D Systems), murine IL-4 (20 ng/mL), murine IL-7 (20
ng/mL; R&D Systems), murine IL-9 (20 ng/mL), murine IL-13 (20 ng/mL),
or human IL-15 (20 ng/mLand 129 ng/mL), with 0.5 mCi of [3H] thymidine
added for the ﬁnal 12 hours.
Degranulation assay of mast cells
BMMCs were cultured at 37°C for 4 days in the presence or absence of
murine IL-4 (20 ng/mL) in RPMI 1640 medium containing 10% (vol/vol)
of X63–IL-3 conditioned medium. BMMCs were then stimulated with
A23187 (200 ng/mL; Sigma, St Louis, MO) at 37°C for 30 minutes.
Enzyme activity of b-hexosaminidase was evaluated for both the superna-
tant and the cell lysate using p-nitrophenyl-N-acetyl b-D-glucosamine
(Sigma) as a substrate.41 The percentage of speciﬁc b-hexosaminidase
release was expressed as: 100 3 supernatant activity/(supernatant
activity 1 cell lysate activity).
Western blotting
After BMMCs were starved for 2 hours from IL-3, the cells were stimulated
with IL-4 (20 ng/mL) or IL-13 (20 ng/mL) at 37°C for 15 minutes. As a
control, freshly isolated murine splenocytes or human peripheral blood
lymphocytes were stimulated with IL-4 or IL-13. The cells were washed
with PBS and lysed in lysis buffer (1% Nonidet P-40, 20 mmol/L Tris-HCl
[pH 8.0], 50 mmol/L NaCl, 2 mmol/L dithiothreitol, 4 mmol/L EGTA, 10
mmol/L NaF, 1 mmol/L Na3VO4,5mg/mL aprotinin, 5 mg/mL leupeptin, 2
mg/mL pepstatin, 0.5 mmol/L phenylmethylsulfonyl ﬂuoride, and 10%
glycerol) on ice for 30 minutes, and cell lysates were prepared by
centrifugation.Atotal of 15 mg of cell lysate was separated on 10% sodium
dodecyl sulfate (SDS) polyacrylamide gels and transferred to Immobilon-P
membranes (Millipore Corp, Bedford, MA). After blocking with PBS
containing 0.15% Tween 20 and 3% bovine serum albumin (BSA) for 1
hour at room temperature, the membranes were incubated with antisera to
mouse Stat6 (M-20) (Santa Cruz Biotechnology Inc, Santa Cruz, CA),
mouse Stat6 (M-200) (Santa Cruz Biotechnology), phospho-Stat6 (New
England Biolabs Inc, Beverly, MA), mouse Stat5 (Transduction Laborato-
ries, Lexington, KY), phospho-Stat5 (New England Biolabs), and mouse
Jak3 (Upstate Biotechnology, Lake Placid, NY) for 1 hour at room
temperature. After washing 3 times with PBS containing 0.15% Tween 20,
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antibodies conjugated with horseradish peroxidase (Amersham Pharmacia
Biotech, Little Chalfont, UK) in PBS containing 0.15% Tween 20 and 3%
BSA for 1 hour at room temperature. The membranes were then washed
with PBS containing 0.15% Tween 20 and developed with an enhanced
chemiluminescent substrate (Roche Diagnostics GmbH, Mannheim,
Germany).
Reverse transcriptase–PCR assay
BMMCs and splenocytes were washed twice with PBS, and total RNAwas
extracted using Isogen reagent (Nippon Gene Co, Tokyo, Japan). The
ﬁrst-strand complementary DNA (cDNA) was then synthesized from total
RNA using moloney murine leukemia virus reverse transcriptase (RT) and
oligo(dT) primers (Pharmacia Biotech, Buckinghamshire, UK). cDNAs
encoding IL-13Ra142 and b-actin (as a control) were ampliﬁed by PCR.
Data analysis
Data are summarized as mean 6 SD. Statistical analysis of the results was
performed by the unpaired t test. P , .05 was considered signiﬁcant.
Results
The number of peritoneal mast cells is decreased
in gc
2 and Jak32 mice
Whereas the importance of SCF and IL-3 in mast cell development
is well documented,1-4 the role of gc-dependent cytokines in mast
cell development is less understood. To determine whether gc and
Jak3 are required for mast cell development in vivo, we analyzed
the number of peritoneal mast cells in gc-deﬁcient (gc
2) and
Jak3-deﬁcient (Jak32) mice.The total cell numbers recovered from
the peritoneal cavity were decreased in gc
2 and Jak32 mice,
resulting mainly from the diminished number of peritoneal CD51
B cells (B-1 cells) (Suzuki et al, article in preparation). In contrast,
the number of peritoneal macrophages was normal in gc
2 and
Jak32 mice (data not shown), consistent with a previous report on
gc
2 mice.32 Although the peritoneal mast cells in gc
2 and Jak32
mice were morphologically indistinguishable from those in WT
mice, the number of mast cells recovered from the peritoneal cavity
was signiﬁcantly decreased in gc
2 and Jak32 mice (WT mice,
5.62 6 0.98 3 104; gc
2 mice, 2.92 6 0.71 3 104; and Jak32 mice,
2.96 6 0.79 3 104; mean 6 SD, n 5 6-8 mice each; P , .01)
(Figure 1A). Consistent with the diminished number of peritoneal
mast cells in gc
2 and Jak32 mice, FACS analysis revealed that
c-kit1 cells in the peritoneal cavity were decreased in gc
2 and
Jak32 mice (data not shown). However, when electrically gated on
c-kit1 peritoneal cells, the intensity of IgE receptors was indistin-
guishable among WT, gc
2, and Jak32 mice (Figure 1B). The
expression levels of Bcl-2 as well as the number of apoptotic cells
(Annexin V binding–positive cells) were also indistinguishable
among c-kit1 peritoneal cells from WT, gc
2, and Jak32 mice (data
not shown). In addition, the number of mast cells (c-kit1IgER1Gr-
12B2202CD42CD82 population) was also decreased in the spleen
in gc
2 and Jak32 mice (WT mice, 1.36 6 0.15 3 104; gc
2 mice,
0.88 6 0.09 3 104; and Jak32 mice, 0.81 6 0.04 3 104; 3-week-
old mice, n 5 5 each; P , .01). These results suggest that gc- and
Jak3-dependent signals play an important role in the proliferation
of mast cells, but not in the maturation of mast cells in vivo.
However, because the numbers of T cells, NK cells, and NK T cells
are severely diminished in gc
2 and Jak32 mice,8-11,35,36 the de-
creased cytokine production from these cells may also contribute to
the impairment in mast cell development. Therefore, we then
studied the role of gc-dependent signals in the proliferation and
survival of cultured mast cells from gc
2 and Jak32 mice.
Development of IL-3–dependent BMMCs is normal
in gc
2 and Jak32 mice
Murine mast cell lines can be established from bone marrow
hematopoietic progenitors in the presence of IL-3.37 To determine
the role of gc-dependent signals in mast cell development, we
prepared primary cultures of IL-3–dependent BMMCs from WT,
gc
2, and Jak32 mice. BMMCs obtained after 4 weeks of culture
were more than 98% mast cells and were morphologically indistin-
guishable among these mice (data not shown). The number of
BMMCs recovered per mouse was also indistinguishable among
these mice (data not shown). Moreover, IL-3–induced proliferation
of BMMCs was normal in gc
2 and Jak32 mice (Figure 2A). The
expression levels of c-kit, FcgII/III, and IgE receptor were also
indistinguishable among BMMCs from WT, gc
2, and Jak32 mice
(Figure 2B). These results indicate that gc- and Jak3-dependent
signals are not essential for IL-3–induced mast cell development
in vitro.
Expression of IL-4Ra, gc, and Jak3 in BMMCs
We next examined the expression of gc, gc-related cytokine
receptors, and Jak3 in BMMCs. As shown in Figure 3, the
expression of IL-2Rb and IL-7Ra was absent in BMMCs from
WT, gc
2, and Jak32 mice. On the other hand, IL-4Ra was equally
expressed in BMMCs fromWT, gc
2, and Jak32 mice (Figure 3).As
expected, BMMCs from gc
2 mice lacked gc expression, conﬁrming
the correct recognition by anti-gc monoclonal antibody (Figure 3).
Figure 1. The number of peritoneal mast cells is decreased in gc
2 and Jak32
mice. (A) Peritoneal mast cells were recovered by lavage and counted in 8- to
12-week-old wild-type (WT), gc-deﬁcient (gc
2), and Jak3-deﬁcient (Jak32) mice.
Peritoneal mast cells were identiﬁed morphologically on cytospin cell preparations
stained with Wright-Giemsa solution. Data are means 6 SD for 6 to 8 mice in each
group. The mean values for gc
2 mice and Jak32 mice are signiﬁcantly different from
the mean value for WT mice, *P , .01. (B) Expression of IgE receptors on c-kit1
peritoneal cells. IgE receptors on peritoneal mast cells were quantiﬁed by ﬁrst
incubating the cells recovered by peritoneal lavage with mouse IgE, then labeling with
anti-IgE FITC, and analyzing by FACS gating on c-kit1 cells. Shown are representa-
tive FACS proﬁles of IgE receptor staining and control staining (dashed lines) on
c-kit1 peritoneal cells from WT, gc
2, and Jak32 mice (n 5 6-8 mice in each group).
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BMMCs from Jak32 mice as compared with those from WT mice
(WT mice, 20.5 6 2.6; Jak32 mice, 36.2 6 3.0; mean ﬂuorescent
intensities for gc staining, n 5 4 each; P , .01) (Figure 3).
Increased gc expression was also observed in c-kit1 peritoneal cells
from Jak32 mice (data not shown). In contrast, the expression of
Jak3 in BMMCs was signiﬁcantly lower in gc
2 mice than that in
WT mice (Figure 4). As expected, Jak3 was undetectable in Jak32
mice (Figure 4).
IL-4 enhances the proliferation, survival, and degranulation
of BMMCs through gc- and Jak3-dependent signaling
IL-4 has been shown to function as a mast cell growth factor.20-23
Although it has been shown that IL-4 can transduce the signals
from 2 types of receptors and that the types of IL-4Rs expressed on
cells differ depending on cell lineage,28,29 it is still unclear which
type of IL-4R is functional on mast cells. To address this question,
we examined the effect of IL-4 on the proliferation of BMMCs
from gc
2 and Jak32 mice. Because IL-4 alone did not induce the
proliferation of BMMCs from WT mice (data not shown), we
examined the synergistic effect of IL-4 on IL-3–induced prolifera-
tion of BMMCs. IL-4 signiﬁcantly enhanced IL-3–induced prolif-
eration of BMMCs from WT mice (IL-3, 14.6 6 0.8 3 103 cpm;
IL-3 1 IL-4, 44.8 6 0.9 3 103 cpm; n 5 5 each; P , .005) (Fig-
ure 5). IL-4 exhibited no effect on IL-3–induced proliferation of
BMMCs from gc
2 and Jak32 mice (Figure 5). These results
indicate that IL-4 induces the proliferation of BMMCs through gc-
and Jak3-dependent signals and that the functional IL-4R on
BMMCs is type I IL-4R. In contrast to IL-4, IL-13, a cytokine that
exhibits IL-4–like functions on B cells43 and endothelial cells44
through type II IL-4R, did not signiﬁcantly enhance the IL-3–
induced proliferation of BMMCs even in WT mice (Figure 5).
We next examined the antiapoptotic effect of IL-4 and IL-13 on
BMMCs. IL-3–deprived BMMCs from WT, gc
2, and Jak32 mice
were cultured with IL-4 (20 ng/mL) or IL-13 (20 ng/mL) for 1 to 5
days, and the cell viability was then determined by FACS. As
shown in Figure 6, the rate of survival after IL-3 withdrawal was
similar among BMMCs from WT, gc
2, and Jak32 mice. IL-4
signiﬁcantly enhanced the survival of BMMCs from WT mice
(control, 9.5% 6 0.5%; IL-4, 64.2% 6 7.0% at day 5; n 5 5 each;
P , .001) (Figure 6). However, IL-4 had no effect on the survival
of BMMCs from gc
2 and Jak32 mice (Figure 6). IL-13 did not
signiﬁcantly affect the survival of BMMCs fromWT, gc
2, or Jak32
mice (Figure 6). These results indicate that IL-4, but not IL-13,
enhances the proliferation and survival of BMMCs through gc- and
Jak3-dependent signaling of type I IL-4R.
To determine whether gc and Jak3 signaling is involved in
IL-4–induced enhancement of mast cell degranulation, we exam-
ined the effect of IL-4 on A23187-induced degranulation of
BMMCs in WT, gc
2, and Jak32 mice. Consistent with a previous
ﬁnding on the role of IL-4 in human mast cell degranulation,45 IL-4
signiﬁcantly enhanced A23187-induced degranulation of BMMCs
from WT mice (P , .01) (Figure 7). In contrast, however, IL-4 did
not increase the degranulation of BMMCs from gc
2 and Jak32
mice (Figure 7). These results indicate that, in addition to its effect
on proliferation and survival, gc and Jak3 signaling is essential for
IL-4–induced enhancement of mast cell degranulation.
Figure 4. Expression of Jak3 in BMMCs. Jak3 expression was analyzed by
Western blotting for BMMCs from WT, gc
2, and Jak32 mice as described in “Materials
and methods.” Shown is a representative anti-Jak3 Western blot from 4 independent
experiments.
Figure 2. Development of IL-3–dependent bone marrow–derived mast cells
(BMMCs) is normal in gc
2 and Jak32 mice. (A) BMMCs (2 3 105/well) were
cultured in the presence of IL-3 at 37°C for 36 hours, and the proliferative responses
were evaluated by the addition of [3H] thymidine for the ﬁnal 12 hours. Data are
means 6 SD for 5 mice in each group. (B) BMMCs from WT, gc
2, and Jak32 mice
were stained with anti–c-kit APC, anti-FcgII/III PE, and IgE FITC, as described in
“Materials and methods.” Shown are representative FACS proﬁles for c-kit, FcgII/III,
and IgE receptor staining from 5 independent experiments. Dashed lines are FACS
proﬁles of negative controls.
Figure 3. Expression of IL-4Ra and gc in BMMCs. BMMCs from WT, gc
2, and
Jak32 mice were analyzed for the expression of IL-2Rb, IL-4Ra, IL-7Ra, and gc on
c-kit1 cells. Shown are representative FACS proﬁles from 4 independent experi-
ments. Dashed lines are FACS proﬁles for the isotype-matched controls.
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in BMMCs
In the IL-4 signaling pathway, the best-studied signaling molecule
is signal transducers and activators of transcription 6 (Stat6).11
Stat6 is also rapidly activated after cellular exposure to IL-13.11
Therefore, we analyzed IL-4– and IL-13–induced Stat6 phosphory-
lation in BMMCs from WT, gc
2, and Jak32 mice. After BMMCs
were deprived of IL-3 for 2 hours, BMMCs were stimulated with
either IL-4 or IL-13 for 15 minutes, and tyrosine phosphorylation
of Stat6 at tyrosine 641 was detected by anti-phospho Stat6
antibody. Surprisingly, IL-4 phosphorylated the 65-kd isoform of
Stat6 in BMMCs from WT mice, whereas IL-4 phosphorylated the
94-kd isoform of Stat6 in WT splenocytes (Figure 8). Reblotting
with anti-Stat6 antibody M200, which recognizes the middle part
of murine Stat6 (AA280-AA480), revealed that BMMCs expressed
the 65-kd isoform of Stat6 but not the 94-kd Stat6 (Figure 8).
Interestingly, the 65-kd isoform of Stat6 was not detected by
anti-Stat6 antibody M20, which recognizes the c-terminus of
murine Stat6, whereas the 94-kd Stat6 in splenocytes was readily
detected by M20 (data not shown). These results suggest that the
65-kd isoform of Stat6 lacks the c-terminus. Although the 65-kd
isoform of Stat6 was equally expressed in BMMCs among WT,
gc
2, and Jak32 mice (Figure 8), IL-4 did not induce the phosphory-
lation of the 65-kd Stat6 in BMMCs from gc
2 or Jak32 mice
(Figure 8). In addition, IL-13 did not induce the phosphorylation of
65-kd Stat6 in BMMCs even from WT mice (Figure 8), whereas
murine IL-13 did phosphorylate the 94-kd Stat6 in human periph-
eral blood lymphocytes (data not shown).
IL-13Ra1 is not expressed in BMMCs
To determine whether IL-13Ra1 is expressed on BMMCs, we
performed RT-PCR analysis for IL-13Ra1 mRNA expression in
BMMCs from WT, gc
2, and Jak32 mice. As shown in Figure 9,
IL-13Ra1 was not detected in BMMCs from WT, gc
2, or Jak32
mice. In contrast, IL-13Ra1 was expressed in splenocytes from
WT mice (Figure 9). The absence of IL-13Ra1 expression on
BMMCs is consistent with our results presented earlier: that IL-4,
but not IL-13, functioned on BMMCs and that IL-4–induced
effects on BMMCs depended on gc and Jak3.
IL-9, but not IL-15, enhances the proliferation and survival
of BMMCs through gc- and Jak3-dependent signaling
As described earlier, IL-4 enhanced the proliferation (Figure 5) and
survival (Figure 6) of BMMCs through gc- and Jak3-dependent
signaling. However, because the number of peritoneal mast cells
was reported to be normal in IL-4–deﬁcient mice,46 defects of IL-4
signals in gc
2 and Jak32 mice may not be responsible for the
diminished mast cell numbers in gc
2 and Jak32 mice. Therefore,
we determined the role of other gc-related cytokines—IL-2, IL-7,
IL-9, and IL-15—in the proliferation of BMMCs. Among these
cytokines, only IL-9 signiﬁcantly enhanced the IL-3–induced
Figure 5. IL-4 induces the proliferation of BMMCs through gc- and Jak3-
dependent signaling. BMMCs from WT, gc
2, and Jak32 mice were cultured in the
presence of IL-3 for 36 hours, with [3H] thymidine added for the ﬁnal 12 hours. Where
indicated, recombinant murine IL-4 or recombinant murine IL-13 was added at 20
ng/mL. Data are means 6 SD for 5 mice in each group. The mean value of
IL-4–stimulated BMMCs is signiﬁcantly different from the mean value of control
BMMCs (IL-3 alone) in WT mice. *P , .005.
Figure 6. IL-4 induces the survival of BMMCs through gc- and Jak3-dependent
signaling. BMMCs from WT, gc
2, and Jak32 mice were cultured in the absence of
IL-3 for 5 days, and cell viability was determined by FACS using PI (5 mg/mL) at days
0, 1, 3, and 5. Where indicated, recombinant murine IL-4 or recombinant murine IL-13
was added at 20 ng/mL. Data are means 6 SD for 5 mice in each group. The mean
value of IL-4–stimulated BMMCs is signiﬁcantly different from the mean value of
control BMMCs in WT mice. *P , .001.
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cpm; IL-3 1 IL-9, 24.3 6 1.8 3 103 cpm; n 5 5 each; P , .005)
(Figure 10). IL-9 had no effect on the proliferation of BMMCs
from gc
2 and Jak32 mice (Figure 10). Interestingly, and inconsis-
tent with a previous report,26 IL-15 did not signiﬁcantly enhance
the proliferation of BMMCs fromWTmice (Figure 10), even when
a high concentration of IL-15 (129 ng/mL) was added to the
BMMC culture (data not shown). The biologic activity of IL-15
was conﬁrmed by IL-2–dependent CTLL-2 proliferation assay, and
the addition of IL-15 achieved a half-maximal proliferation of
CTLL-2 cells at approximately 0.01 ng/mL(data not shown).
We then determined the effects of IL-9 and IL-15 on the
survival of IL-3–deprived BMMCs. Whereas IL-9 enhanced the
survival of BMMCs from WT mice (control, 9.7% 6 0.6%; IL-9,
50.1% 6 6.5% at day 5; n 5 5; P , .005), IL-9 did not signiﬁ-
cantly affect the survival of BMMCs from gc
2 and Jak32 mice
(Figure 11). These results indicate that the antiapoptotic effect of
IL-9 on BMMCs depends on gc and Jak3. Again, IL-15 did not
signiﬁcantly enhance the survival of BMMCs even in WT mice
(Figure 11).
IL-4 enhances the survival of peritoneal mast cells
through gc- and Jak3-dependent signaling
Finally, we studied the role of gc and Jak3 signaling in IL-4– and
IL-9–induced survival of freshly isolated peritoneal mast cells. As
shown in Figure 12, IL-4 signiﬁcantly increased the survival of
peritoneal mast cells from WT mice (control, 44.4% 6 6.1%; IL-4,
67.3% 6 7.0% at 24 hours; n 5 4 each; P , .01). In contrast, IL-9
exhibited only a marginal effect on the survival of peritoneal mast
cells from WT mice. Consistent with the in vitro experiments on
BMMCs (Figures 6 and 11), IL-4 as well as IL-9 exhibited no effect
on the survival of peritoneal mast cells from gc
2 and Jak32 mice
(Figure 12). These results indicate that IL-4 enhances the survival
of peritoneal mast cells through gc- and Jak3-dependent signaling.
Discussion
Previous studies have shown that gc- and Jak3-dependent signals
play the essential regulatory roles in T-cell and NK cell develop-
ment.8-11,35,36 In this study, we show that gc- and Jak3-dependent
signaling induces the proliferation and survival of murine mast
Figure 7. IL-4 induces the degranulation of BMMCs through gc- and Jak3-
dependent signaling. BMMCs from WT, gc
2, and Jak32 mice were cultured for 4
days in the presence of IL-3 alone or IL-3 plus murine IL-4 (20 ng/mL). BMMCs were
then stimulated with A23187 (200 ng/mL) for 30 minutes, and the percentage of
speciﬁc b-hexosaminidase release was determined as described in “Materials and
methods.” Data are means 6 SD for 4 mice in each group. The mean value of
IL-4–stimulated BMMCs is signiﬁcantly different from the mean value of the
corresponding BMMCs without IL-4 stimulation in WT mice. *P , .01.
Figure 8. IL-4–induced phosphorylation of 65-kd Stat6 isoform in BMMCs is gc-
and Jak3-dependent. BMMCs from WT, gc
2, and Jak32 mice were washed with
PBS, cultured for 2 hours in the absence of IL-3, and stimulated with IL-4 or IL-13 (20
ng/mL) for 15 minutes.After washing with PBS, cell lysates were prepared, separated
on a 10% SDS gel, and blotted with antisera to either phospho-Stat6 or Stat6 (M200).
As a control, cell lysates from IL-4–stimulated WTsplenocytes were used. Shown is a
representative blot from 4 independent experiments.
Figure 9. IL-13Ra1 is not expressed on murine BMMCs. Total RNAwas prepared
from BMMCs, and RT-PCR analysis for IL-13Ra1 and b-actin (as a control) was
performed as described in “Materials and methods.” As a control, splenocytes from
WTmicewereused.Shownarerepresentativedatafrom5independentexperiments.
Figure 10. IL-9 induces the proliferation of BMMCs through gc- and Jak3-
dependent signaling. BMMCs from WT, gc
2, and Jak32 mice were cultured in the
presence of IL-3 for 36 hours, with [3H] thymidine added for the ﬁnal 12 hours. Where
indicated, recombinant human IL-2, recombinant murine IL-7, recombinant murine
IL-9, or recombinant human IL-15 was added at 20 ng/mL. Data are means 6 SD for
5 mice in each group. *P , .005.
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receptor component, IL-4 and IL-9, but not IL-2, IL-7, or IL-15,
enhanced the proliferation and survival of BMMCs from WT mice
and that the effects of IL-4 and IL-9 were absent in BMMCs from
gc
2 and Jak32 mice (Figures 5, 6, 10, and 11). We also found that
IL-4Ra, gc, and Jak3, but not IL-2Rb, IL-7Ra, or IL-13Ra1, were
expressed in BMMCs (Figures 3, 4, and 9). Our ﬁndings of the
decreased number of peritoneal mast cells in gc
2 and Jak32 mice
also suggest an important role of gc- and Jak3-dependent signals in
the proliferation and survival of mast cells in vivo (Figure 1).
Our results indicate that IL-4–induced proliferation and survival
of murine mast cells are mediated through type I IL-4R. It has been
shown recently that type I IL-4R is a heterodimer of IL-4Ra and gc,
that type II IL-4R is a heterodimer of IL-4Ra and IL-13Ra1, and
that the usage of IL-4R differs depending on cell lineage.28,29 We
found that IL-4 enhanced the proliferation and survival of BMMCs
from WT mice but not from gc
2 or Jak32 mice (Figures 5 and 6)
and that IL-4Ra and gc were expressed in BMMCs (Figure 3). In
contrast, although a previous study reported that IL-13 induced the
proliferation of a murine mast cell line,47 we found that IL-13 did
not signiﬁcantly enhance the proliferation and survival of BMMCs
even from WT mice (Figures 5 and 6) and that IL-13Ra1 was not
expressed in BMMCs (Figure 9). Therefore, although increasing
evidence suggests that IL-13 may play an important role in allergic
inﬂammation,48,49 mast cells may not be a target of IL-13. In
addition to type I and type II IL-4Rs, the experiments using
chimeric proteins that were constructed with the cytoplasmic
domain of IL-4Ra and an extracellular domain of erythropoi-
etin,50,51 CD8,51 or c-kit52 suggested that the homodimerization of
IL-4Ra could transduce IL-4 signals. However, our ﬁnding that
gc-deﬁcient BMMCs, which express IL-4Ra, did not respond to
IL-4 stimulation also indicates that the expression of IL-4Ra alone
is not sufﬁcient to transduce IL-4 signals in mast cells.
The best-characterized molecule downstream of gc/Jak3 in IL-4
signals is Stat6.11 Interestingly, whereas Stat6 is essential for
IL-4–induced proliferation of T cells,53-55 IL-4–induced prolifera-
tion of BMMCs is slightly increased in the absence of Stat6.56 In
addition, mastocytosis induced by in vivo administration of IL-4
was rather enhanced in Stat6-deﬁcient mice.57 In the present study,
we showed that the 65-kd isoform of Stat6, which lacked the
c-terminus, was predominantly expressed in mast cells (Figure 8).
Moreover, we found that the 65-kd isoform of Stat6 was phosphor-
ylated by IL-4 in a gc- and Jak3-dependent manner (Figure 8). Our
ﬁndings are in agreement with the recent observation by Sherman
et al58 that murine mast cells preferentially express 65-kd Stat6.
The 65-kd isoform of Stat6 is apparently different from the
previously reported Stat6 isoforms in human ﬁbroblast, Stat6b and
Stat6c, which encode an NH2-terminal truncation and an SH2-
domain deletion, respectively.59 Because deletion mutants of Stat6
that lack the c-terminus still bind to the Stat6-recognition site of
DNAbut lose transcriptional activity,60 it is possible that the 65-kd
isoform of Stat6 may function as a negative regulator of transcrip-
tion. At present, it is unknown how the 65-kd isoform of Stat6 is
Figure 12. IL-4 enhances the survival of peritoneal mast cells through gc- and
Jak3-dependent signaling. Peritoneal cells from WT, gc
2, and Jak32 mice were
cultured in the presence of IL-4 or IL-9 for 24 hours, and cell viability of c-kit1 cells was
determined by FACS as described in “Materials and methods.” Data are means 6 SD
for 4 mice in each group. The mean value of IL-4–stimulated peritoneal mast cells is
signiﬁcantly different from the mean value of control peritoneal mast cells in WTmice.
*P , .01.
Figure 11. IL-9 induces the survival of BMMCs through gc- and Jak3-dependent
signaling. BMMCs from WT, gc
2, and Jak32 mice were cultured in the absence of
IL-3 for 5 days, and cell viability was determined by FACS using PI (5 mg/mL) at days
0, 1, 3, and 5. Where indicated, recombinant murine IL-9 or recombinant human IL-15
was added at 20 ng/mL. Data are means 6 SD for 5 mice in each group. *P , .05,
**P , .005.
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extract from splenocytes was mixed with the extract from BMMCs
and incubated at 37°C, the 94-kd Stat6 in splenocytes was cleaved
to 65 kd (our unpublished data), suggesting that the 65-kd Stat6 in
mast cells is generated by cleavage of mature protein rather than by
alternative splicing of mRNA. In addition to Stat6, it has been
reported recently that IL-4 induces the proliferation of murine
pro–B-cell line Ba/F3 through activation of Stat5.61 However, we
observed no Stat5 phosphorylation in IL-4–stimulated BMMCs
(our unpublished data). Thus, it is unlikely that Stat5 activation is
responsible for IL-4–induced proliferation and survival of BM-
MCs. Taken together, our results indicate that IL-4 enhances the
proliferation and survival of mast cells in a gc- and Jak3-dependent
manner, but not in a Stat6- or Stat5-dependent manner.
We also show that IL-9 enhances the proliferation and survival
of BMMCs through gc- and Jak3-dependent signaling (Figures 10
and 11). IL-9 is a Th2-cell–derived cytokine with pleiotropic
effects on various cell types, including mast cell growth.24,25,62,63
Because the number of peritoneal mast cells was reported to be
normal in IL-4–deﬁcient mice,46 it is conceivable that the dimin-
ished peritoneal mast cell numbers in gc
2 or Jak32 mice (Figure
1A) may result from the absence of signaling via IL-9 or an
undeﬁned gc/Jak3-dependent cytokine. IL-9 or IL-9R knockout
mice could be valuable in further investigating this issue.
IL-15 was also previously shown to function as a mast cell
growth factor through an undeﬁned IL-15R X, but not through an
IL-2Rb/gc heterodimer.26 However, we found that IL-15 had no
signiﬁcant effect on the proliferation and survival of BMMCs even
in WT mice (Figures 10 and 11). In addition, in parallel experi-
ments, we found that IL-15 did induce the proliferation of CTLL-2
cells at 0.01 ng/mL, but IL-15 did not enhance the proliferation of
BMMCs even at 129 ng/mL. Because Tagaya et al26 reported that
the activity of IL-15 on mast cell proliferation differed between
batches of human IL-15, unknown factor(s) possibly contaminated
in some batches of IL-15 might induce the expression of IL-15R X,
and thereby IL-15 might enhance the proliferation of BMMCs in a
gc-independent manner.
In summary, we have shown that gc- and Jak3-dependent
signaling is essential for IL-4– and IL-9–induced proliferation and
survival of murine mast cells. We have also shown that the effects
of IL-4 on mast cells are mediated by type I IL-4R and that IL-13
exhibits no IL-4–like effects on mast cells because of the absence
of IL-13Ra1. In addition, IL-4 phosphorylates the 65-kd isoform of
Stat6 in mast cells through gc- and Jak3-dependent signaling.These
results suggest that gc- and Jak3-dependent signaling has an
important role in the mast cell expansion of Th2-cell–mediated
inﬂammatory responses.
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